HOPE Therapeutics Secures Financing For Ketamine Clinic Expansion
HOPE Therapeutics Secures Financing For Ketamine Clinic Expansion
HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), announced plans to acquire a network of interventional psychiatry clinics, focusing on ketamine treatments. The acquisition and financing agreements, valued at $30 million, are backed by a qualified lender. The company signed a non-binding Term Sheet for five operational clinics in the Western United States, generating over $10 million in annual revenue.
NRx藥業（NASDAQ:NRXP）的子公司HOPE Therapeutics宣佈計劃收購一家介入性精神病診所網絡，重點關注氯胺酮治療。這項價值3000萬美元的收購和融資協議得到合格貸方支持。該公司與西部美國五家運營診所簽署了一份非約束性期限表，年營業收入超過1000萬美元。
The clinics will focus on treating conditions like suicidal depression, treatment-resistant depression (TRD), and PTSD. HOPE Therapeutics aims to create a unified, patient-centered approach, combining pharmaceutical therapies and FDA-approved technologies like Transcranial Magnetic Stimulation (TMS).
這些診所將專注於治療自殺性抑鬱、難治性抑鬱症（TRD）和創傷後應激障礙（PTSD）。HOPE Therapeutics旨在打造統一的以患者爲中心的方法，結合藥品療法和美國食品藥品監督管理局（FDA）批准的技術，如經顱磁刺激（TMS）。
Co-CEOs Jonathan Javitt and Matthew Duffy emphasized the importance of this initiative. "We are delighted to take the critical first steps towards developing a network of clinics that can provide the highest possible level of care."
聯席首席執行官喬納森·賈維特和馬修·達菲強調了這一舉措的重要性。「我們很高興邁出關鍵的第一步，發展一家能夠提供最高水平護理的診所網絡。」
HOPE Therapeutics projects annualized revenues of $100 million by mid-2025 through continued clinic acquisitions and anticipates potential operations in the United States, France, and the United Kingdom.
HOPE Therapeutics預計到2025年年中通過持續收購診所實現年收入達1億美元，並預計在美國、法國和英國可能開展業務。
Read Also: The Potential Of Ketamir-2: A Safer Treatment For Mental Health Disorders And Neuropathic Pain, IND Filing Expected By Year-End
閱讀更多：Ketamir-2的潛力：更安全的治療精神健康疾病和神經病痛，預計年底前提交IND申請
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.
獲取Benzinga獨家分析以及關於大麻行業和市場的最新資訊，每天免費發送到您的郵箱。點擊此處訂閱我們的新聞稿。如果您認真對待業務，那麼不能錯過。
Ketamine Clinics And Treatments
氯胺酮診所和治療
Ketamine, originally an anesthetic, has gained significant attention in recent years for its off-label use in treating mental health conditions such as depression, PTSD, and treatment-resistant depression (TRD). The rise in ketamine assisted therapies is largely due to its rapid-acting properties, which offer relief where traditional antidepressants often fall short. As research progresses, treatments are becoming more refined, with new delivery methods like nasal sprays, topical creams and patient-controlled infusions enhancing accessibility and effectiveness.
氯胺酮最初是一種麻醉藥，近年來因其在治療抑鬱症、創傷後應激障礙（PTSD）和難治性抑鬱症（TRD）等精神健康疾病的非標籤使用而受到廣泛關注。氯胺酮輔助療法的崛起主要是因爲其快速作用特性，能夠在傳統抗抑鬱藥物常常無法奏效時提供緩解。隨着研究的不斷進展，治療變得更加精細，新的給藥方式如鼻噴劑、局部乳膏和患者控制的輸注提高了可及性和有效性。
Photo: Courtesy of Sonis Photography via Shutterstock
圖片：由 shutterstock 提供的 Sonis Photography 公司的圖像。
譯文內容由第三人軟體翻譯。